|Assessment Status||Assessment Process complete|
|Indication||For the treatment of moderate to severe rheumatoid arthritis.|
|Full submission received from Applicant||13/03/2010|
|NCPE assessment completed||02/09/2010|
|NCPE assessment outcome||Reimbursement not Recommended.|
The review group did not consider certolizumab cost-effective at the submitted price in September 2010.
The HSE has approved reimbursement following confidential price negotiations.